Opioid substitution treatments in France: recent data


Opioid substitution treatments in France : recent data - 2014

Tendances n°94, OFDT, 6 p.
October 2014

Nearly twenty years after they were first launched in France (1995), opioid substitution treatments (OSTs) remain a cornerstone of the country’s harm reduction policy. As part of medical, psychological and social treatment, OSTs promote access to care for opioid-dependent drug users and reduce morbidity, mortality and social harm.

This analysis presents a summary of the latest OST data available. It is a follow-up to a series of studies initiated in 2002 of opioid substitution medication (OSM) reimbursement data. Other sources are also used in this issue of Tendances, which begins with presenting an estimate of the number of people receiving OSTs in France and in Europe. Then, there is a description of the relevant population, distinguishing between approaches to follow- up and treatment dispensing as well as a discussion of the issue of misuse and diversion. There is also a discussion on the control measures put in place and OSM related morbidity and mortality risks. Finally, there is a brief discussion on “the French model” of substitution therapy.

Authors : Anne-Claire Brisacier, Cédric Collin

Download the PDF file (1,33 Mo)

Drugs in Europe

2016 EMCDDA European Drug Report

- Drug facts, figures and analyses: across Europe and by country
- Latest trends and legal, political and social responses
- Selected issues: Vulnerable groups of young people; National drug-related research in Europe; Towards a better understanding of drug-related public expenditure in Europe

Country situation summaries

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) website has a concise overview for each EU Member State on their national drug situation, as well as legal texts in their original formats, an indispensable tool for monitoring and analysing legislative developments in the Member States.

The European Union and the drug phenomenon

The European Union & the drug phenomenon : Frequently asked questions , joint publication between the EMCDDA and the European Commission, october 2010, 12 p.